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A B S T R A C T
AMP-activated protein kinase (AMPK) is a key regulator of cellular energy homeostasis, acting as a sensor of
energy and nutrient status. As such, AMPK is considered a promising drug target for treatment of medical
conditions particularly associated with metabolic dysfunctions. To better understand the downstream effectors
and physiological consequences of AMPK activation, we have employed a chemical genetic screen in mouse
primary hepatocytes in an attempt to identify novel AMPK targets. Treatment of hepatocytes with a potent and
specific AMPK activator 991 resulted in identification of 65 proteins phosphorylated upon AMPK activation,
which are involved in a variety of cellular processes such as lipid/glycogen metabolism, vesicle trafficking, and
cytoskeleton organisation. Further characterisation and validation using mass spectrometry followed by im-
munoblotting analysis with phosphorylation site-specific antibodies identified AMPK-dependent phosphoryla-
tion of Gapex-5 (also known as GTPase-activating protein and VPS9 domain-containing protein 1 (GAPVD1)) on
Ser902 in hepatocytes and starch-binding domain 1 (STBD1) on Ser175 in multiple cells/tissues. As new pro-
mising roles of AMPK as a key metabolic regulator continue to emerge, the substrates we identified could
provide new mechanistic and therapeutic insights into AMPK-activating drugs in the liver.
1. Introduction
AMP-activated protein kinase (AMPK) is a key regulator of cellular
energy homeostasis, acting as a sensor of energy and nutrient status
through primarily sensing adenine nucleotide levels [1–3]. AMPK is a
heterotrimer comprising a catalytic α-subunit and regulatory β- and γ-
subunits. Multiple isoforms encoded by distinct genes exist (α1 and α2,
β1 and β2, and γ1, γ2, and γ3), which can theoretically form several
distinct heterotrimeric combinations, with the isoform expression pro-
files varying amongst cells/tissues and also species. Under conditions of
cellular energy stress, which leads to an increase in AMP-to-ATP or
ADP-to-ATP ratios, AMPK is activated and switches off anabolic pro-
cesses that consume ATP, while activating catabolic processes that
generate ATP in order to restore energy balance [1,2,4–6]. This is
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achieved through phosphorylation of a plethora of downstream targets
[7], including acetyl CoA carboxylase (ACC) 1 and 2, which modulate
lipid synthesis and oxidation, respectively [8,9], TBC1D1, which pro-
motes glucose transport in muscle [10,11], and regulatory-associated
protein of mTOR (Raptor), which inhibits protein synthesis and cell
growth [12]. More recently, it has been demonstrated that AMPK
controls mitochondrial homeostasis and adipose tissue browning
through mitochondrial fission factor (MFF) and likely also through
targets yet to be identified [13–15]. Due to such key roles that AMPK
plays in integrating signalling pathways for maintenance of energy
homeostasis, AMPK is considered a promising drug target for treatment
of medical conditions associated with the metabolic syndrome, such as
insulin resistance and type 2 diabetes [16–19]. However, there is
growing evidence that AMPK regulates biological processes not con-
ventionally linked to metabolic processes, including cell division, au-
tophagy, and cell invasion [20–22]. This growing list of emerging roles
for AMPK in diverse biological contexts has drawn major attention to
AMPK as a drug target for cancer and other diseases. In parallel,
however, it has also raised concerns regarding potential side effects,
which may arise as a consequence of chronic AMPK activation. To
address this, major efforts have been made to understand and design
isoform−/complex-specific roles and activators for AMPK, respectively
[7,23], and to reveal AMPK substrates and their function [14,20,21,24].
Although various approaches have been developed for identification of
AMPK targets, the majority of the studies performed previously utilised
immortalised cancer cells or fibroblasts. To better understand the
downstream effectors and physiological consequences of AMPK acti-
vation, it will be critical to take the cell- and activator-specific context
into account.
Hepatic metabolism plays an important role in regulation of whole-
body energy balance, as liver is the major site for storage and release of
glucose/carbohydrates and for fatty acid synthesis [25]. Several lines of
evidence have demonstrated that hepatic AMPK gets activated in re-
sponse to physiological stimuli, including exercise [26] and nutrient
deprivation/starvation [27], and inhibited in response to physio-
pathological conditions such as chronic alcohol consumption [28].
Moreover, it is established that antidiabetic drugs, metformin [29,30]
and several natural products [31] (e.g. salicylate [32], berberine [33]),
robustly activate hepatic AMPK. Collectively, hepatic AMPK has a
wider role in coordinating metabolism under various physiological/
pathophysiological settings likely through regulating a plethora of
downstream targets. In the current study, we have performed a che-
mical genetic screen in primary hepatocytes to identify new direct
targets of AMPK. We report the identification of 65 proteins that are
potentially direct targets of AMPK, and we further characterised the
phosphorylation sites Ser902 on Gapex-5 (also known as GTPase-acti-
vating protein and VPS9 domain-containing protein 1 (GAPVD1)) and
Ser175 on starch-binding domain 1 (STBD1).
2. Materials and methods
2.1. Materials
Materials used include 5-aminoimidazole-4-carboxamide riboside
(AICAR, A611700; Toronto Research Chemicals), A769662 (S2697;
Selleck Chemicals), mass spectrometry grade trypsin (V528A;
Promega), creatine kinase (C3755; Sigma), phosphatase inhibitor
cocktail 2 and 3 (P5726 and P0044; Sigma), cOmplete protease in-
hibitor cocktail EDTA-free (11,836,170,001; Roche), p-ni-
trobenzylmesylate (PNBM; ab138910; Abcam), N6-(2-Phenylethyl)
adenosine-5’-O-(3-thiotriphosphate) (N6-phenethyl-ATPγS; P 026;
Biolog), Protein G Sepharose (P3296; Sigma), FLAG-M2 resin (A2220;
Sigma) and NHS-activated Sepharose (17-0906-01; GE Healthcare). 991
(5-[[6-chloro-5-(1-methylindol-5-yl)-1H-benzimidazol-2-yl]oxy]-2-me-
thyl-benzoic acid) (CAS#: 129739-36-2) was described previously [14].
COS-1 (CRL-1650) and AML12 (CRL2254) cell lines were obtained from
American Type Culture Collection. General and specific cell culture
reagents were obtained from Thermo Fisher Scientific. All other mate-
rials unless otherwise indicated were from Sigma.
2.2. Antibodies
Total acetyl-CoA carboxylase (ACC; #3676), phospho-ACC (S79;
#3661), total Raptor (#2280), phospho-Raptor (S792; #2083), total
AMPKα (#2532), phospho-AMPKα (T172; #2535), total AMPKβ1
(#4182) and phospho-(S/T) AMPK substrate motif (#5759, lot #7)
antibodies were from Cell Signaling Technology. Antibodies against α-
tubulin (T6074) and FLAG (F7425) were from Sigma. Antibody against
AMPKγ1 was from OriGene Technologies (TA300519), antibodies
against thiophosphate-ester were from Abcam (for immunoprecipita-
tion: ab133473; for immunoblot: ab92570), antibodies against Gapex-5
were from Bethyl Laboratories (A302-116A; raised against internal se-
quence) and Sigma (SAB1401626; raised against N-terminal sequence)
and antibodies against STBD1 were a kind gift from Dr. David Stapleton
(University of Melbourne; raised against N-terminal peptide 343–358)
or obtained from Proteintech Group (11842-1-AP; raised against whole
protein). Horseradish peroxidase-conjugated secondary antibodies were
from Jackson ImmunoResearch Europe. Site-specific rabbit polyclonal
were generated by YenZym Antibodies by immunisation with a phos-
phorylated peptide of the human sequence (CPERLVRSR-*S-SDIVS-
amide for pSer902 Gapex-5, the prefix * denotes the phosphorylated
residue) or a combination of two phosphorylated peptides of the human
and mouse sequences (CFAEKLP-*S-SNLLKNR-amide and CVAAKLP-*S-
SSLLVDR-amide for pSer175 STBD1, CWEMVPRHS-*S-WGDVG-amide
and CWEVVSRHS-*S-WGSVG-amide for pSer211 STBD1).
2.3. Animals
Animal studies were approved by the local Ethical Committee of the
Canton of Vaud, Switzerland, and performed under license number
2570. C57BL/6N mice were obtained from Charles River Laboratories.
Generation of liver-specific AMPKα1/α2 knockout mice has been de-
scribed previously [34]. Experiments using hepatic AMPKα1/α2 double
knockout and its control mice were performed under the approval of
the ethics committee from University Paris Descartes (no.
CEEA34.BV.157.12) and the French authorisation to experiment on
vertebrates (no.75–886) in accordance with the European guidelines.
Animal studies for Fig. 4D using C57BL/6 wildtype and muscle-specific
KD AMPK overexpressing mice [35] were approved by the Danish An-
imal Experiments Inspectorate (no. 2016-15-0201-01043).
2.4. Cloning, mutagenesis and adenovirus production
The coding regions of human AMPKα2 (NM_006252), AMPKβ1
(NM_006253) and AMPKγ1 (NM_002733) were amplified from muscle
RNA (Agilent) using SuperScript III One-step RT-PCR kit (Thermo
Fisher Scientific). Human STBD1 (NM_003943.4) was also amplified
from muscle RNA. The resulting PCR products were either ligated into
intermediate vector pSC amp/kan (Agilent) or digested with the re-
levant restriction enzymes and ligated directly into expression vectors.
The coding region of human Gapex-5 (NM_001282680.1) was amplified
from IMAGE clone 40,083,103 obtained from Source BioScience. Site
directed mutagenesis was carried out according to the Quick Change
method (Agilent) using KOD polymerase (Novagen). The sequences of
all constructs were verified in-house using BigDyeR Terminator 3.1 kit
and 3500XL Genetic analyzer (Applied Biosystems).
In order to obtain adenovirus particles the AdEasy vector system
was used according to the manufacturer's protocol (Agilent). The
coding regions of the different human AMPK subunits (α2, α2-M93G,
β1, γ1) were cloned into the intermediate pShuttle-CMV vector, which
was transformed into chemically competent BJ5183 E.coli cells car-
rying the pAdEasy-1 plasmid. The colonies containing the recombinant
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plasmids were selected on kanamycin plates and the candidates were
verified with restriction digests and by capillary sequencing. The
pAdeasy vectors have been packaged using CAP cells derived from
human amniocytes by Sirion Biotech.
2.5. General cell culture and mouse primary hepatocytes
AML12 cells were cultured in DMEM/F12 supplemented with 10%
foetal calf serum, 1× Insulin-Transferrin-Selenium (ITS G; Gibco
41,400,045) and 100 nM dexamethasone. COS-1 cells were cultured in
DMEM supplemented with 10% foetal calf serum. Cells were trans-
fected with DNA using polyethylenimine, treated and harvested 36 h
post-transfection. Cells were washed with ice-cold PBS and scraped into
lysis buffer (50mM tris pH 7.5, 1 mM EDTA, 1mM EGTA, 0.27M su-
crose, 1% (w/v) Triton X-100, 20mM glycerol-2-phosphate, 50mM
NaF, 5mM sodium pyrophosphate, 0.5 mM PMSF, 1mM benzamidine,
1 mM dithiothreitol, 1 mM Na3VO4). Lysates were clarified at 3,500 g
for 15min at 4 °C and normalised using Bradford reagent and bovine
serum albumin (BSA) as standard.
Primary mouse hepatocytes were isolated from C57BL/6N mice
(12–14weeks old) or from liver-specific AMPKα1/α2 knockout and
control mice as previously described [36,37].
2.6. Incubation of isolated mouse skeletal muscle ex vivo
Mice were anaesthetised (6mg pentobarbital and lidocaine/100 g
body weight, intraperitoneal injection) and extensor digitorum longus
(EDL) muscles were rapidly removed and mounted on an incubation
apparatus. The EDL muscle was incubated in KRH-buffer (supple-
mented with 2mM pyruvate, 8 mM mannitol, 1× amino acids (Sigma
M5550) and 5mM Hepes at 30 °C) in the presence of 4mM AICAR or
vehicle for 40min as previously described [38].
2.7. Immunoprecipitation and immunoblotting
For immunoprecipitation, lysates were incubated with antibody and
5 μl of Protein G Sepharose or 5 μl FLAG-M2 resin on a vibrating plat-
form shaker (1000 rpm) for 16 h at 4 °C. Immunoprecipitate was eluted
from the resin by boiling in Laemmli buffer. For Western blotting, cell
lysates and tissue homogenates were denaturated in Laemmli buffer,
separated by SDS-PAGE and transferred to nitrocellulose membrane.
Membranes were blocked for 1 h in 20mM tris (pH 7.6), 137mM NaCl,
0.1% (v/v) Tween-20 (TBST) containing 5% (w/v) skimmed milk.
Membranes were incubated in primary antibody prepared in TBST
containing 1% (w/v) BSA overnight at 4 °C. Detection was performed
using horseradish peroxidase-conjugated secondary antibodies and en-
hanced chemiluminescence reagent.
2.8. Substrate screen in cells using ATP-analogue specific AMPK
Primary mouse hepatocytes were isolated and plated on collagen-
coated 10-cm dishes at a density of 5× 106 cells per dish as described
above. 5 h after plating, cells were switched to overnight medium. 1 h
later, cells were transduced with adenovirus for AMPKα2 (WT or
M93G), AMPKβ1 and AMPKγ1 (multiplicity of infection (MOI) of 1 for
each AMPK subunit). 16 h after starting transduction, dishes were wa-
shed twice with warm PBS and fresh overnight medium was added. 6 h
later, cells were washed twice in warm PBS and AMPK substrate la-
belling with ATPγS analogue was performed [20]. Labelling was per-
formed in 20mM Hepes pH 7.4 buffer containing 100mM KOAc, 5mM
NaOAc, 2mM Mg(OAc)2, 1 mM EGTA, 10mM MgCl2, 0.5mM DTT,
5mM creatine phosphate, 50 μg/ml creatine kinase, 20 μg/ml digitonin,
3 mM GTP, 0.1 mM ATP, 0.1 mMN6-phenethyl-ATPγS, 1× phosphatase
inhibitor cocktails 2 and 3, and 1× cOmplete protease inhibitor. Ad-
ditionally, 30 μM 991 was added to the labelling buffer to activate
AMPK. Cells were labelled during 20min at room temperature while
gently shaking. The labelling reaction was stopped by adding 20mM
EDTA and cells were lysed by adding 1% (w/v) Triton X-100, followed
by vortexing and sonication for 30 s. Lysates were then cleared by
centrifugation at 3,500 g for 15min. Lysates were alkylated for 1 h at
room temperature on a shaker (1400 rpm) using 2.5mM PNBM. The
buffer was then exchanged to RIPA buffer (50mM tris pH 7.4, 150mM
NaCl, 1 mM EDTA, 1% (w/v) Triton X-100, 0.5% (w/v) sodium deox-
ycholate, 0.1% (w/v) sodium dodecyl sulfate (SDS), 20mM glycerol-2-
phosphate, 2.5 mM sodium pyrophosphate, 0.5 mM PMSF, 1mM ben-
zamidine, and 1mM Na3VO4) using a Sephadex G-25 column. Samples
were then immunoprecipitated using anti-thiophosphate ester antibody
or rabbit IgG control antibody cross-linked to NHS-activated Sepharose
according to the manufacturer's instructions.
2.9. Trypsin digestion and MS analysis
Immunoprecipitated proteins were denatured in Laemmli buffer,
alkylated using iodoacetamide and separated by SDS-PAGE on NuPAGE
4–12% bis-tris gels (Thermo Fisher Scientific). Gels were stained with
colloidal Coomassie and regions of interest were excised. Gel pieces
were destained by successive washing (10min, 30 °C) in water, 50%
acetonitrile, 0.1M triethylammonium bicarbonate (TEAB, pH 8.5) and
50mM TEAB in 50% acetonitrile. Gel pieces were dehydrated in 100%
acetonitrile and dried before rehydration in 25mM TEAB containing
5 μg/ml trypsin for 16 h (30 °C). The digestion products were then ex-
tracted sequentially with one volume of 100% acetonitrile (15min,
30 °C) and one volume of 25% acetonitrile and 1.25% formic acid
(15min, 30 °C). The resulting supernatants were pooled and dried.
Peptides were re-dissolved in 5% acetonitrile / 0.25% formic acid.
Reversed-phase liquid chromatography tandem MS (RPLC-MS/MS)
analysis was performed on a LTQ-Orbitrap Velos coupled to a Proxeon
Easy-LC. The peptide mixtures were loaded onto a C18 guard column
(1.9 μm; 0.1×20mm) and separated on a C18 in-house packed emitter
(1.9 μm; 0.075×150mm) over a 55min linear gradient (5% to 45%B.
A: 2% acetonitrile, 0.1% formic acid B: 80% acetonitrile, 0.1% formic
acid). The Orbitrap was set to analyse the survey scans (m/z 350 to
1,600) at 60,000 resolution and the top 10 ions in each duty cycle were
selected for MS/MS in the LTQ linear ion trap with collision-induced
dissociation (CID) (normalised collision energy (NCE) 36%). The data
was searched against the Mus musculus Uniprot database (26/05/2015
release; 50,807 entries) using Mascot (2.4.1). Scaffold (4.4.3) was used
to validate MS/MS based peptide and protein identifications. Peptide
identifications were accepted if they could be established at greater
than 95.0% probability as specified by the Peptide Prophet algorithm,
resulting in a peptide false discovery rate (FDR) of 0.78% [39]. Protein
identifications further required at least 2 unique peptides.
For analysis of STBD1 sites phosphorylated in vivo, dried peptides
were dissolved in 3% acetonitrile/ 0.1% formic acid. RPLC-MS/MS
analysis was performed on an LTQ-Orbitrap Velos coupled to a Proxeon
Easy-LC using the same chromatography as described above. The
Orbitrap was set to analyse the survey scans (m/z 320 to 1,600) at
30,000 resolution and the top 10 ions in each duty cycle were selected
for MS/MS in the LTQ linear ion trap with collision-induced dissocia-
tion (CID) (NCE 36%; multistage activation was enabled). The data was
searched against the Homo sapiens Uniprot database (20/12/2012 re-
lease; 148,212 entries) using Mascot (2.4.1). All Mascot result files were
loaded into Scaffold (4.4.3). Peptide and protein thresholds were set to
95.0% and mascot peptide ion scores were required to be greater than
30, resulting in a peptide FDR of 0.36%. A minimum of 2 unique
peptides were required to report protein identification.
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3. Results
3.1. Chemical genetic screen for identification of AMPK substrates in
primary mouse hepatocytes
We performed a chemical genetic screen in primary mouse hepa-
tocytes to identify novel AMPK substrates following the work flow il-
lustrated in Fig. 1A. The chemical genetic technology was originally
developed based on the evidence that the ATP-binding pocket of pro-
tein kinases contains a conserved gatekeeper residue in close contact
with the N6 position of the adenine ring of ATP. Replacement of this
residue with a smaller amino acid (typically glycine) enables the
gatekeeper mutant protein kinase to utilise ATP analogues containing
bulky groups at the N6 position [40]. In contrast, the bulky ATP ana-
logues are poor substrates for wild-type (WT) kinases due to the steric
hindrance of the gatekeeper residue. N6-modified ATPγS nucleotides
are also accepted by the ATP-analogue specific kinase, and the trans-
ferred thiophosphate can be alkylated and recognised by a specific
monoclonal antibody (Fig. 1A) [40]. This chemical genetic approach
allows specific labelling of direct substrates of a protein kinase in cells.
A previous study has already identified and confirmed methionine 93 as
the gatekeeper residue of AMPKα2 and demonstrated that substitution
of methionine 93 to glycine (M93G) transformed the WT into an ATP-
analogue specific (AS) form [20].
We transduced mouse primary hepatocytes with adenoviral vector
encoding catalytic AMPKα2 WT or M93G mutant in combination with
other vectors encoding regulatory AMPKβ1 and AMPKγ1 subunits. We
noticed that even though AMPKα2 WT and M93G were transduced at
equal MOI, expression of AMPKα2 M93G was markedly lower com-
pared to WT (Fig. 1B, left panel). This was consistently observed across
multiple experiments (data not shown), however whether it was due to
instability of the M93G mutant or another mechanism is unknown. We
estimate that levels of catalytic α2 subunit expression achieved in
WT−/M93G-infected cells are ~10–20-fold higher than endogenous
α2 protein expression (data not shown). Coincidentally, the AMPKβ1
and γ1 subunits were also expressed at modestly lower levels when co-
transduced with the M93G mutant (Fig. 1B, left panel). Following the
adenoviral transduction, hepatocytes were chemically permeabilised
and incubated with ATPγS analogue for 20min in the presence of the
specific and potent AMPK activator 991, a small-molecule benzimida-
zole derivative [41,42]. After alkylation and buffer exchange (as de-
scribed in Materials and methods), direct immunoblotting of the ATPγS
analogue-treated lysates with an anti-thiophosphate-ester (thioP) anti-
body resulted in a robust and specific labelling of thio-phosphorylated
proteins in the AMPKα2 M93G, but not WT-expressing cells- (Fig. 1B),
as previously reported [20]. Immunoprecipitation of the labelled ly-
sates with the thioP antibody coupled to NHS-activated Sepharose resin
confirmed efficient isolation of the thio-phosphorylated proteins
(Fig. 1C). It can be noted that the coupling of the thioP antibody to the
resin for immunoprecipitation was also efficient, as only a small
amount of IgG heavy and light chains (which react with the secondary
antibody) was detected. In order to identify AMPKα2 M93G-mediated
thio-phosphorylated proteins by mass spectrometry (MS), we used 2mg
of alkylated lysates from the experiments shown in Fig. 1B (right
panel). The lysates were subjected to immunoprecipitation with the
thioP antibody or rabbit IgG and the immunoprecipitates were pro-
cessed for MS analysis as described in the Materials and methods. Ex-
tracted peptides analysed by LC-MS/MS were searched against the
mouse UniPROT database and the amount of protein detected was
quantified by total spectral counting. We performed two independent
experiments in which 917 protein clusters were identified with a
minimum of two peptides (protein and peptide threshold at 95%).
Criteria for positive hits were defined as being either unique to the
M93G-transduced sample or at least two-fold enriched in the M93G-
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transduced samples as compared to the WT-transduced sample. Across
biological repeats, 272 proteins were identified as positive hits, of
which 65 were common to both biological replicates (Table 1). For
those proteins, there was a good correlation (R2 of 0.85) of total spectra
counts detected between the two runs, demonstrating that the current
experimental approach had high reproducibility (Fig. 1D). Amongst the
65 proteins identified were well established (ACC1, ACC2) or recently
reported (MBS85 (also known as PPP1R12C), PAK2 and IRSp53 (also
known as BAIAP2)) [20] substrates of AMPK. Based on our primary
interest in the role of AMPK in nutrient transport [2,10,43] and gly-
cogen metabolism [44–46], we decided to focus on Gapex-5 (which has
been proposed to play a role in vesicle trafficking) and STBD1 (which is
known as starch/glycogen binding protein).
3.2. Identification and validation of Gapex-5 and STBD1 as novel
substrates of AMPK
In the experimental approach used in this study, it was not possible
to directly determine the specific site of thio-phosphorylation in the
protein/peptides. Using the MS data from our previous study [14], we
identified a phospho-peptide (SR*SSDIVSSVR, the prefix * denotes the
phosphorylated residue) which was uniquely present in samples from
hepatocytes treated with a combination of two AMPK activators (AICAR
and A769662) [36,47], but not in samples from vehicle-treated control
or AMPK-deficient hepatocytes. This phospho-peptide is proteotypic to
Gapex-5, and the phosphorylated residue corresponds to Ser902 (of
mouse and also human Gapex-5). Ser902 Gapex-5 is well conserved
across the species examined and falls optimally into the AMPK phos-
phorylation motif [21] (Fig. 2A). In order to validate AMPK-mediated
phosphorylation of Gapex-5, we cloned human Gapex-5 and custom-
generated a phosphosite-specific antibody for detection of Ser902 (p-
Ser902 as described in Materials and methods). We transfected COS-1
cells with FLAG-tagged WT or non-phosphorylatable S902A mutant of
Gapex-5 and treated the cells with either 991 or vehicle for 30min
followed by immunoblot analysis (Fig. 2B). As anticipated, 991 treat-
ment resulted in a robust increase in phosphorylation of AMPK and its
established bona fide substrate ACC. We observed that 991 increased
Gapex-5 Ser902 phosphorylation in WT, but not in S902A mutant
AMPK, confirming the MS result and also specificity of the p-Ser902
antibody (Fig. 2B). We further verified specific phosphorylation of
Gapex-5 Ser902 using the AMPK phosphorylation motif antibody. The
expected molecular weight is 164 kDa and we observed that the major
band for FLAG-Gapex-5 was detected just below the 250 kDa marker
(when proteins were resolved in 8% tris-glycine SDS-PAGE). Upon
longer exposure of the immunoblots, an additional band was detected
around 150 kDa. This band could represent a degradation product (C-
terminal truncated) of the full-length (N-terminal FLAG-tagged Gapex-
5) protein (Fig. 2B). We then sought to investigate whether endogenous
Gapex-5 is regulated by AMPK in intact cells. We first assessed Gapex-5
expression in a panel of mouse tissues using two different antibodies;
one raised against the N-terminus and the other against an internal
sequence of human Gapex-5. Indeed, Gapex-5 was detectable in most
mouse tissues analysed (including liver), but not detectable in kidney
(Fig. 2C). Consistent with the results obtained with recombinant FLAG-
Gapex-5 (Fig. 2B), we observed that endogenous Gapex-5 also runs just
below the 250 kDa marker (Fig. 2C), and the specificity of the antibody
was also confirmed on tissues from Gapex-5 knockout zebrafish that we
generated (Supplemental Fig. S3E). We next wanted to validate AMPK-
mediated phosphorylation of endogenous Gapex-5 in intact hepato-
cytes. In the AML12 mouse hepatocyte cell line, Gapex-5 was phos-
phorylated on Ser902 upon treatment with AICAR and A769662, which
was detected using either the AMPK phospho-motif antibody or the
phosphosite-specific antibody for Ser902 following immunoprecipita-
tion with a total Gapex-5 antibody (Fig. 2D). We next treated hepato-
cytes, isolated from hepatic AMPKα1/α2 double knockout (DKO) and
floxed control mice, with AICAR and A769662. As shown in Fig. 2E,Ta
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upon treatment with the compounds, Gapex-5 Ser902 phosphorylation
was increased in control hepatocytes, but not in AMPK DKO hepato-
cytes. Taken together, these results demonstrate that Gapex-5 is phos-
phorylated at Ser902 in hepatocytes in an AMPK-dependent manner,
which could likely account for the direct AMPK phosphorylation event
identified in our chemical genetic screen.
We next wanted to validate/establish if STBD1 is a novel AMPK
substrate. Consistent with the results presented in a previous study
[48], STBD1 is predominantly expressed in liver, skeletal muscle and to
a lesser extent in the spleen of the mouse tissues analysed (Fig. 3A).
Next, we wanted to identify specific site(s) on STBD1 phosphorylated
by AMPK. Inspection of the STBD1 protein sequence, both manually
and also using AMPK motif scan by Scansite (http://scansite.mit.edu/),
revealed that several sites conform to the AMPK phosphorylation motif
to varying degrees. However, contrary to our expectation, im-
munoblotting of the 991-treated cell lysates with the phospho-AMPK
Fig. 2. Biochemical characterisation of Gapex-5 as an AMPK substrate. (A) Sequences of Gapex-5 from chimpanzee (Uniprot identifier: K7D792), mouse (Q6PAR5),
rat (D3ZBJ3), clawed frog (A2RV61) and zebrafish (E7F237) were aligned to the human sequence (Q14C86) using ClustalW (www.clustal.org). The sequence
surrounding Ser902 of human Gapex-5 is shown. The sequence for the optimal AMPK motif was created using WebLogo (weblogo.berkeley.edu) and the sequences
surrounding a list of in vivo AMPK phosphorylation target sites as compiled by Schaffer et al. [21]. (B) COS-1 cells were transfected with human FLAG-Gapex-5
wildtype (WT) or S902A mutant. Cells were then treated with vehicle (0.1% DMSO) or 10 μM 991 for 30min. Gapex-5 was immunoprecipitated with FLAG-M2
antibody from 100 μg cell lysates. Western blotting was performed using the immunoprecipitates and input lysates (20 μg) using the indicated antibodies. Im-
munoblots shown are representative of two independent experiments. (C) Tissue protein extracts were prepared from C57BL/6N mice. Total cell lysates (200 μg)
were immunoprecipitated using anti-Gapex-5 antibody (internal sequence) and Protein G Sepharose. Western blotting was performed using two different anti-Gapex-
5 antibodies. Immunoblots shown are representative of two independent experiments. (D) AML12 mouse hepatocytes were treated with vehicle or a combination of
1 mM AICAR and 30 μM A769662 for 30min. Total cell lysates (200 μg) were immunoprecipitated using anti-Gapex 5 (internal sequence) or non-specific control
antibody (rabbit IgG) and Protein G Sepharose. Western blotting of the immunoprecipitates and input lysates (20 μg) was performed using the indicated antibodies.
Immunoblots shown are representative of two independent experiments. (E) Primary hepatocytes were isolated from AMPKα1/α2 liver-specific double knockout
(DKO) and control AMPKα1lox/loxα2lox/lox mice (CON). Plated hepatocytes were treated with vehicle or a combination of 0.3 mM AICAR and 10 μM A769662 for
45min. Total cell lysates (400 μg) were immunoprecipitated using anti-Gapex-5 (internal sequence) or non-specific control antibody (rabbit IgG) and Protein G
Sepharose. Western blotting of the immunoprecipitates and input lysates (20 μg) was performed using the indicated antibodies. Immunoblots shown are re-
presentative of two independent experiments.
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motif antibody failed to detect a signal on ectopically expressed FLAG-
STBD1 (data not shown). We therefore decided to perform unbiased
phospho-peptide mapping by MS. FLAG-STBD1 was transiently over-
expressed in COS-1 cells and they were treated with vehicle or 991
(30 μM) for 1 h. Recombinant STBD1 was affinity purified with a FLAG
antibody, digested in-gel with trypsin and the resulting peptides were
subjected to MS analysis (Fig. 3B). The MS/MS analysis resulted in
peptide coverage of STBD1 ranging from 68% to 77% and revealed
multiple phosphorylated residues (Fig. 3C). Of those residues, Ser175
and Ser188 were consistently identified phosphorylation sites in all
three replicates under the 991-treated conditions. We also inspected the
extracted ion chromatograms (XIC) corresponding to those residues
(LP*SSNLLK for Ser175 and AKEEM*SLSDLNSQDR for Ser188). Indeed,
the XIC clearly confirmed the presence of the phosphorylated phospho-
(caption on next page)
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peptide only in 991-treated samples (Fig. 3D). Both of the identified
991-regulated sites fit relatively well with the broadly defined AMPK
phosphorylation motif [12], with hydrophobic alanine and leucine re-
sidues at the−5 and+4 positions, with respect to the phosphorylation
site, and a basic lysine residue at the −3 or− 4 position (Fig. 3E). In
addition to the 991-regulated phosphorylation sites identified by MS,
during manual inspection of the STBD1 sequence, we noticed Ser211
and its surrounding sequence conforming to the optimal AMPK motif
(Fig. 3E). We then generated phosphosite-specific antibodies for the
well-conserved (across mammals) residues (Ser175 and Ser211) but not
the less conserved Ser188 site (Fig. 3E). We ectopically overexpressed
(FLAG-tagged) WT or non-phosphorylatable (Ser175Ala or Ser211Ala)
STBD1 in COS-1 cells and the cells were treated with 991. This treat-
ment comparably promoted phosphorylation of AMPK and ACC, while
it robustly stimulated phosphorylation of WT FLAG-STBD1 on Ser175,
but not the Ser175Ala mutant (Fig. 3F). In contrast, while Ser211
phosphorylation was readily detected under basal (vehicle-treated)
condition, it was not increased with 991 treatment under the condition
tested.
We next investigated Ser175 phosphorylation of endogenous STBD1
upon AMPK activation in mouse primary hepatocytes. Treatment with
AICAR robustly increased pSer175-STBD1 in a dose-dependent manner
and followed the increase of AMPK phosphorylation on Thr172 and of
the bona fide AMPK substrate Raptor on Ser792 (Fig. 4A and B). Fur-
thermore, increased pSer175-STBD1 was also observed upon treatment
of primary mouse hepatoctyes with 991 (Supplemental Fig. S4A and
S4B). In order to establish AMPK dependence of Ser175-STBD1 phos-
phorylation, we treated hepatocytes, isolated from hepatic AMPK
double KO and control mice, with single (10 μM 991) or dual (0.3 mM
AICAR+10 μM A769662) AMPK activator treatment (Fig. 4C). Con-
sistent with our previous observations [36,47], dual treatment (AICAR/
A769662) caused a profoundly higher phosphorylation of AMPK and its
known substrate Raptor compared to single treatment. Notably, the
dual treatment markedly increased Ser175 phosphorylation of STBD1,
which was accompanied by an upward shift of the immune-reactive
band, possibly due to additional phosphorylation events beside Ser175
on STBD1. Under these conditions, the total STBD1 antibody used was
unable to detect the total STBD1 protein, possibly due to significant
modulation of the epitope sequence via multiple phosphorylation re-
sulting in insufficient recognition by the antibody (Fig. 4C). Further-
more, we confirmed that Ser175 phosphorylation in vehicle- and acti-
vator-stimulated conditions was totally AMPK-dependent, as the
phosphorylation signals were abolished in the AMPK DKO hepatocytes
(Fig. 4C). To investigate STBD1 phosphorylation in skeletal muscle,
extensor digitorum longus (EDL) muscle was isolated from wild-type
mice and mice with muscle-specific overexpression of kinase-dead
AMPK (AMPK-KD) [35] and incubated with vehicle or 4mM AICAR. As
shown in Fig. 4D, AICAR treatment increased AMPK (Thr172) and ACC
(Ser79) phosphorylation in muscles from wild-type mice but not in
muscles isolated from AMPK-KD mice. The antibody raised against
pSer175-STBD1 also shows a non-specific immune-reactive band just
above 37 kDa in skeletal muscle, nevertheless the antibody detected
increased Ser175-STBD1 phosphorylation (just below 37 kDa) upon
AICAR treatment of muscle from wild-type mice, but this effect was lost
in EDL muscle isolated from AMPK kinase-dead mice (Fig. 4D). In
summary, these results establish STBD1 Ser175 as a novel AMPK target
site both in liver as well as in skeletal muscle.
4. Discussion
To better understand physiological consequences of AMPK activa-
tion, identifying the downstream effectors in a cell- and activator-spe-
cific context is essential. With previous screens for cellular AMPK tar-
gets having been performed in immortalised cell lines such as HEK293T
[20], U2OS [21] or L6 myotubes [49], we have focused on identifying
AMPK targets in primary hepatocytes, such as to account for a cell- and
tissue-specific role of AMPK. To do that, we have recently established
an MS-based analysis of proteins isolated from mouse hepatocyte ex-
tracts using a phospho-AMPK substrate motif antibody [14]. Even
though the motif affinity proteomics approach is simple and valid in
identifying cellular AMPK targets, it has a limitation in that it has a bias
towards proteins containing the strict AMPK consensus motif with a
leucine at the−5 and an arginine at the−3 position [14]. To overcome
this limitation and implement a complementary approach to more
comprehensively identify AMPK-dependent cellular targets, we have
undertaken a chemical genetic approach using ATP-analogue specific
AMPK, which is expected to have the same substrate specificity as
compared to endogenous AMPK [20]. We report 65 potential direct
targets of AMPK in primary hepatocytes, amongst them well established
(ACC1, ACC2) or recently reported (MBS85 (also known as PPP1R12C),
PAK2 and IRSp53 (also known as BAIAP2)) [20] substrates of AMPK.
Based on literature analysis, the identified proteins are involved in
lipid, carbohydrate and nucleotide metabolism, as well as immune re-
sponse, cell adhesion, cytoskeleton organisation, protein trafficking and
other cellular processes as summarised in Table 1. We also compared
the current hits with the ones obtained through the aforementioned
motif proteomics approach, in which 57 proteins were described as
AMPK-dependent phosphorylation targets [14]. Although both studies
were performed in the same cellular system, only 6 proteins (ACC1,
Gapex-5, COBLL1, NBCe1, MTSS1 and NAP1) were in common between
the two studies. The limited overlap can be explained by several rea-
sons: For example, overexpression of ATP-analogue specific AMPK
might affect subcellular localisation of the kinase, and introduction of a
mutation in the kinase ATP-binding pocket could affect substrate
phosphorylation kinetics. Collectively, this suggests that because of
biases introduced by the methodology, as well as issues of sensitivity,
either method only detects a subset of all AMPK substrates in hepato-
cytes. This is further corroborated by the fact that ubiquitous bona fide
substrates such as Raptor and Ulk1 were not identified in our screens.
AMPK has previously been shown to regulate vesicle trafficking
Fig. 3. Biochemical characterisation of STBD1 as an AMPK substrate. (A) Tissue extracts were prepared from C57BL/6N mice. Western blotting using 20 μg lysates
was performed using two different anti-STBD1 antibodies. Immunoblots are representative of 3 independent experiments. (B) COS-1 cells were transfected with
human FLAG-STBD1. Cells were then serum-starved for 4 h before treatment with vehicle (0.1% DMSO) or 30 μM 991 for 1 h. FLAG-STBD1 was affinity purified with
FLAG-M2 resin from 500 μg cell lysates, separated by SDS-PAGE and the gel was stained using Coomassie dye. (C, D) Gel pieces containing STBD1 from Fig. 3B (red
boxes) were excised for further processing (trypsin digestion and tandem mass spectrometry analysis). (C) Sequence coverage (merged results for 3 samples) for
samples from vehicle-treated (left panel) and 991-treated cells (right panel) are shown (grey shading), along with phosphorylated residues (green shading). Residues
phosphorylated uniquely in samples from 991-treated cells and that were present in all 3 samples are marked with a red box. (D) Extracted ion chromatograms are
shown for two phospho-peptides, LPsSNLLK and AKEEmsLSDLNSQDR (lowercase denotes phosphorylated serine or oxidized methionine residue). For each phospho-
peptide, ion intensities were normalised to the same scale between vehicle- and 991-treated samples. Peptides were identified by MS/MS spectra exclusively after 991
treatment and recorded at the time indicted with the arrow. NL: normalization level. (E) Sequences of STBD1 from chimpanzee (Uniprot identifier: H2QPQ7), mouse
(Q8C7E7), rat (Q5FVN1), clawed frog (A9JTP4) and zebrafish (E7FH49) were aligned to the human sequence (O95210) using ClustalW (www.clustal.org). The
regions around Ser175, Ser188 and Ser211 of human STDB1 are shown. The sequence for the optimal AMPK motif was created using WebLogo (weblogo.berkeley.
edu) and the in vivo sequences of known AMPK substrates according to Schaffer et al. [21]. (F) COS-1 cells were transfected with human FLAG-STBD1 wild-type,
Ser175Ala or Ser211Ala mutant. Cells were then treated with vehicle (0.1% DMSO) or 30 μM 991 for 30min. Lysates (10 μg) were separated by SDS-PAGE and
immunoblotted using the antibodies as indicated. Immunoblots are representative of 2 independent experiments.
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under certain conditions, notably in the context of CD36-mediated fatty
acid uptake [50–53] and GLUT4-mediated glucose uptake [8,54,55]
into striated muscle. The latter has furthermore been shown to depend
on phosphorylation of the Rab GTPase-activating protein (RabGAP)
TBC1D1 on Ser237 by AMPK [10,56–58]. Moreover, AMPK has been
implicated in endocytic processes, such as regulation of GLUT1 en-
docytosis through phosphorylation of TXNIP [59]. Gapex-5 (also known
as RAP6, gene name gapvd1) was identified as an AMPK substrate in the
present study as well as in our AMPK motif screen [14] and we de-
monstrated AMPK-dependent Gapex-5 phosphorylation on Ser902 in
intact primary hepatocytes (Fig. 2). Gapex-5 is an endosomal protein
which contains a Ras GTPase-activating protein (RasGAP) domain at
the N terminus and a C-terminal Vps9 domain (Supplemental Fig. S3A),
the latter serving as a guanine exchange factor (GEF) domain for Rab5
[60]. Gapex-5 has been implicated in both fluid-phase as well as re-
ceptor-mediated endocytosis in various cell lines [60–62]. To in-
vestigate a potential involvement of AMPK and Gapex-5 in regulation of
endocytosis in hepatocytes, we measured uptake of low-density lipo-
protein (LDL) and epidermal growth factor (EGF) into primary mouse
hepatocytes. We found that specific AMPK activation with 991 slowed
down endosomal trafficking for both LDL and EGF (Supplemental Fig.
S1A,B). Whereas Gapex-5 knockdown had no effect on EGF trafficking,
it resulted in reduced LDL endocytosis (Supplemental Fig. S1C-E). This
is in agreement with the reported function of Gapex-5 as a GEF for Rab5
since uptake of LDL, which is a classical clathrin-dependent endocytosis
target, was shown to be largely dependent on Rab5 [63]. EGF on the
other hand has been shown to enter the cell through multiple pathways
[64,65].
In adipocytes, Gapex-5 has been implicated in regulation of GLUT4
vesicle trafficking [66,67]. Gapex-5 has been proposed to cause in-
tracellular retention of GLUT4 vesicles through activation of Rab31, a
Rab5 family member, in the cytosol [67]. Upon insulin stimulation,
Gapex-5 was shown to translocate to the plasma membrane, leading to
activation of Rab5 [66]. Accordingly, knockdown of Gapex-5 in 3 T3-L1
A B
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Fig. 4. Phosphorylation of STBD1 in primary hepatocytes and skeletal muscle. (A,B) Primary hepatocytes were isolated from C57BL/6N mice, and treated with
vehicle or AICAR at the indicated concentrations for 1 h. (A) Western blotting was performed using total lysates (20 μg) using the indicated antibodies, and detection
was performed with the Odyssey CLx Imaging System (LI-COR Biosciences). Immunoblots are representative of 2 independent experiments. (B) Western blots were
quantified using Image Studio v3.1 (LI-COR Biosciences). Phosphorylated protein intensities were normalised to β-actin, and fold increase over vehicle-treated
condition is shown as mean ± standard error (n=2), fitted with a sigmoidal dose-response (variable slope) curve (GraphPad Prism 7). (C) Primary hepatocytes
were isolated from AMPKα1/α2 liver-specific double knockout (DKO) and control AMPKα1lox/loxα2lox/lox mice (CON). The hepatocytes were treated with vehicle, a
combination of 0.3 mM AICAR and 10 μM A769662, or 10 μM 991 for 45min. Western blotting was performed using total lysates (10 μg) using the indicated
antibodies. Immunoblots are representative of 2 independent experiments. (D) EDL muscles from wild-type (WT) mice or mice with muscle-specific overexpression of
kinase-dead AMPK (AMPK-KD) were isolated and incubated with vehicle or 4 mM AICAR for 40min. Muscles were homogenised and protein extracts (20 μg) were
analysed by immunoblotting with the indicated antbodies. Representative immunoblots are shown, n=4.
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adipocytes has been shown to reduce insulin-stimulated glucose uptake
[66]. To confirm this result, we have knocked down Gapex-5 using
three different siRNA in 3 T3-L1 adipocytes (Supplemental Fig. S2A).
We observed that Gapex-5 knockdown only reduced insulin-stimulated
glucose uptake at low doses of insulin (1 nM), whereas at high doses
(100 nM), insulin-stimulated glucose uptake was not affected by Gapex-
5 knockdown (Supplemental Fig. S2B), in contrast to previous reports
[66]. In adipocytes, the effect of AMPK activation on glucose uptake
remains unclear [68]. Since we also observed AMPK phosphorylation of
Gapex-5 pSer902 in adipocytes (Supplemental Fig. S2C), it would be
interesting to further investigate the effect of specific AMPK activation
on glucose uptake in adipocytes and the potential involvement of
Gapex-5 phosphorylation by AMPK.
Homozygous deletion of gapvd1 in mouse is embryonically lethal
(reported by the International Mouse Phenotyping Consortium for
strain RRID:MMRRC_043884-UCD). Gapex-5 is highly conserved in
zebrafish (78% protein identity, 86% similarity as assessed using NCBI
blastp), with Ser896 corresponding to Ser902 in human Gapex-5
(Supplemental Fig. S3A). This has prompted us to generate Gapex-5
deficient zebrafish by introducing a frameshift mutation in the gapvd1
gene using CRISPR/Cas9 (Supplemental Fig. S3B). Both heterozygous
and homozygous carriers of the knockout allele were viable into
adulthood (Supplemental Fig. S3C), however abnormal jaw and rough
skin were observed with complete penetrance in adult knockout ani-
mals (Supplemental Fig. S3D). Using the tissue from Gapex-5 knockout
zebrafish, we confirmed the identity of the immunoreactive band of
250 kDa as Gapex-5 (Supplemental Fig. S3E). Thus, having shown that
Gapex-5 knockout zebrafish are viable opens the door for further stu-
dies of Gapex-5 in an animal model.
We also characterised a second protein identified in our screen, the
glycogen-binding protein STBD1, showing AMPK-dependent phos-
phorylation on Ser175 (Figs. 3 and 4). AMPK binds glycogen through
the carbohydrate binding module located in the regulatory β subunit
[69–71], but the physiological role of AMPK binding to glycogen is not
understood. A proposed role for AMPK in glycogen metabolism is in-
hibition of glycogen synthesis through direct phosphorylation of muscle
and liver glycogen synthase [45,72,73], but it is unclear under which
physiological conditions AMPK activation would lead to inhibition of
glycogen synthesis [74]. STBD1 (also known as Genethonin 1 or GENX-
3414) has been reported to bind glycogen [48,75,76], associate with
the endoplasmic reticulum and mitochondria [77], and to interact with
GABARAPL1, a member of the ATG8 family of proteins involved in
autophagy [48,78]. Therefore, STBD1 has been proposed to play a role
in glycophagy, a cellular process in which glycogen is transferred to the
lysosome and degraded by lysosomal α-glucosidase (GAA). This
pathway is defective in Pompe disease (glycogen storage disease type II;
OMIM #232300), where GAA deficiency leads to severe accumulation
of glycogen and damage to tissues [74]. Interestingly, GAA/STBD1
double knockout mice exhibited reduced accumulation of lysosomal
glycogen in liver, but not in skeletal muscle [79]. To date, separate
characterisation of the STBD1 knockout mouse has not been reported.
In the brain, glycogen is present at much lower amounts than in
skeletal muscle and liver but has nonetheless been shown to have im-
portant functions [80]. Moreover, pathological accumulation of gly-
cogen in neurons, such as in Lafora disease (OMIM #254780) results in
neurodegeneration [81]. Although we didn't detect STBD1 in total brain
lysates (Fig. 3A), STBD1 was detected in neuronal cell lines and AMPK
activation increased phosphorylation of STBD1-Ser175 in these cells
(Supplemental Fig. S4C). Whether AMPK phosphorylation of STBD1
represents an additional mechanism to regulate glycogen metabolism in
different tissues such as liver, muscle or brain, remains to be de-
termined.
There are several interesting hits identified in the current screen.
For example, carnitine palmitoyltransferase 1 (CPT1) is an enzyme lo-
calised in the outer mitochondrial membrane that converts long-chain
acyl-CoA species to their corresponding long-chain acyl-carnitines for
transport into the mitochondria for oxidation [2,82]. Given it is es-
tablished that AMPK regulation of ACC controls the level of malonyl-
CoA which in turn is a negative regulator of CPT1, it would be of in-
terest to explore the role that AMPK has on CPT1 in terms of its func-
tionality. In addition, AMP-deaminase (AMPD) is involved in regulation
of energetic metabolism in mammalian cells and it catalyses conversion
of AMP to IMP. AMPD inhibitors have been proposed as useful agents
for boosting AMPK activation in cells and tissues during ATP-depletion
[83]. In mouse liver, a loss of function study has demonstrated that
AMPD2 plays an important role in maintaining metabolic/glucose
homeostasis [84]. Whether AMPK has role in modulating AMPD2 ac-
tivity is unknown, and this warrants future investigation.
Recent pre-clinical studies using novel small-molecule AMPK acti-
vators have shown that AMPK activators hold promise as glucose-
lowering agents [18,19]. Exemplified by the cardiac hypertrophy en-
countered in one study [19], more work is nevertheless needed to un-
derstand the tissue-specific effects of chronic AMPK activation. To that
end, our study describes a systematic approach for identification of
direct AMPK targets and subsequent biochemical characterisation,
which will advance our understanding of AMPK downstream action in a
cell- or tissue-specific manner.
5. Conclusions
Here we report a chemical genetic screen for AMPK substrates in
primary mouse hepatocytes and identify 65 proteins phosphorylated by
ATP-analogue specific AMPK. We further established AMPK-dependent
phosphorylation of endogenous Ser902-Gapex-5 in hepatocytes and
Ser175-STBD1 in both hepatocytes and skeletal muscle. Further study
of the functional importance of these phosphorylation events is how-
ever necessary. This study expands on our knowledge of AMPK down-
stream targets in hepatocytes.
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